Speaker Lecture Titles
Partial list of confirmed speakers.
Name |
Country |
Lecture Title |
|---|---|---|
| Claudio A. Cuello | Canada | TBA |
| Johannes Attems | UK | DEMENTIA WITH LEWY BODIES AND PARKINSON’S DISEASE; SAME LEWY BODIES BUT DIFFERENT DISEASES |
| Kaj Blennow | Sweden | BLOOD AND CSF BIOMARKERS FOR AD – THE PATH TO IMPLEMENTATION IN CLINICAL ROUTINE |
| Mathew Blurton Jones | USA | EXAMINING THE THERAPEUTIC POTENTIAL OF STEM CELL DERIVED MICROGLIA |
| Guojun Bu | USA | APOE-TREM2 AXIS IN MICROGLIAL RESPONSES AND ALZHEIMER’S DISEASE |
| Luc Buee | France | NANOBODIES/VHH, AN ALTERNATIVE TO ANTI-TAU IMMUNOTHERAPY |
| Frédéric Checler | France | SPREADING OF APP-DERIVED FRAGMENTS: NEW TOOLS, NEW DATA |
| Gaël Chételat | France | ALZHEIMER’S DISEASE BRAIN LESION TOPOGRAPHY AND PROPAGATION |
| Ornit Chiba-Falek | USA | APOE-TARGETED EPIGENOME THERAPY: TOWARDS PRECISION MEDICINE IN ALZHEIMER’S DISEASE |
| Jeffrey Cummings | USA | THE ALZHEIMER’S DISEASE DRUG DEVELOPMENT PIPELINE: THE CHANGING LANDSCAPE OF TREATMENTS AND TRIALS |
| Bart De Strooper | Belgium | PRESENILIN/Γ-SECRETASE ALLOSTERIC MODULATORS: TOO LATE FOR PRECISION MEDICINE IN ALZHEIMER’S DISEASE? |
| Marc Diamond | USA | TAU PROPAGATION INTO CELLS AND THROUGH NETWORKS |
| Karen Duff | UK | TAUOPATHY MECHANISMS IN FTD AND AD |
| Dustin Mergott | USA | DISCOVERY AND EARLY CLINICAL DEVELOPMENT OF ORAL ANTI-TAU THERAPIES AS THE NEXT GENERATION OF DISEASE-MODIFYING TREATMENTS |
| Nick Fox | UK | “PARADOXICAL” CEREBRAL VOLUME CHANGES ON MRI IN ANTI-AMYLOID IMMUNOTHERAPY TRIALS: POSSIBLE EXPLANATIONS AND PLAUSIBILITY |
| Dan Frenkel | Israel | TARGETING METABOLIC CHANGES IN ASTROCYTES TOWARDS THERAPEUTIC INTERVENTION IN ALZHEIMER’S DISEASE |
| Giovanni Frisoni | SWITZERLAND | INTERVENTIONS FOR SECONDARY PREVENTION IN BRAIN HEALTH SERVICES FOR DEMENTIA |
| Luz Frolich | Germany | CLINICAL MEANINGFULNESS OF CLINICAL TRIAL DATA IN EARLY ALZHEIMER’S DISEASE |
| James Galvin | USA | PRECISION MEDICINE APPROACHES TO ENHANCE STUDIES OF BRAIN HEALTH AND THE RISK OF ALZHEIMER’S DISEASE |
| Angela Genge | Canada | THERAPEUTIC INNOVATIONS IN ALS |
| Klaus Gerwert | Germany | MISFOLDING OF ALPHA-SYNUCLEIN AS EARLY BIOMARKER FOR PARKINSON`S DISEASE AND SYNUCLEINOPATHIES |
| Alison Goate | USA | GENETIC RISK FOR AD: WHAT THIS TELLS US ABOUT MECHANISM OF DISEASE |
| Gabriel Gold | Switzerland | MICROINFARCTS AND MICROBLEEDS: THE SEARCH FOR MECHANISMS |
| Christian Haass | Germany | POSITIONING MICROGLIAL FUNCTION AND DYSFUNCTION WITHIN THE AMYLOID CASCADE |
| Oskar Hansson | Sweden | USE OF NOVEL BIOMARKERS FOR NEURODEGENERATIVE DISEASES IN CLINICAL TRIALS AND PRACTICE |
| Elizabth Head | USA | ALZHEIMER DISEASE IN PEOPLE WITH DOWN SYNDROME – THE FUTURE OF CLINICAL TRIALS |
| Susanne Hendrix | USA | AN OVERVIEW OF CLINICAL TRIAL RESULTS IN ALZHEIMER’S DISEASE IN THE PAST 2 DECADES WITH A FOCUS ON TIME SAVINGS |
| Michael Heneka | Germany | MICROGLIAL METABOLISM DETERMINES AMYLOID BETA CLEARANCE FUNCTION |
| Joachim Herz | USA | TARGETING ENDOSOMAL PH HOMEOSTASIS FOR AD PREVENTION |
| Makoto Higuchi | Japan | ASSOCIATION AND DISSOCIATION BETWEEN NEUROIMAGING-BASED AND PLASMA BIOMARKERS FOR AD |
| Henne Holstege | The Netherlands | ESCAPING DEMENTIA UNTIL EXTREME AGES: WHAT CAN COGNITIVELY HEALTHY CENTENARIANS TEACH US? |
| David Holtzman | USA | APOE3CH INFLUENCES THE MICROGLIAL RESPONSE TO AΒ PLAQUES AND SUPPRESSES AΒ-INDUCED TAU SEEDING AND SPREADING |
| Bradley Hyman | USA | DRIVERS OF DISEASE PROGRESSION |
| Costantino Iadecola | USA | NEUROVASCULAR DETERMINANTS OF NEURODEGENERATION: FROM MECHANISMS TO THERAPIES |
| Ole Isacson | USA | LIPID DYSHOMEOSTASIS MECHANISMS IN LEWY BODY DEMENTIA AND ALZHEIMER’S DISEASE |
| Takeshi Iwatsubo | Japan | PREDICTION OF BRAIN AMYLOID PET STATUS BY PLASMA AMYLOID-Β42 AND P-TAU217 BIOMARKERS IN THE JAPANESE PRECLINICAL AD COHORT |
| Clifford Jack | USA | UPDATE ON NIA AA RESEARCH FRAMEWORK |
| William Jagust | USA | OPTIMAL OUTCOMES IN COGNITIVE AGING |
| Jung-Hwan Shin | Korea | DEVELOPMENT OF A VIDEO-BASED MONITORING PLATFORM FOR COMPREHENSIVE MOTOR SYMPTOMS OF PARKINSON’S DISEASE |
| Miia Kivipelto | Sweden | PRECISION PREVENTION OF ALZHEIMER´S DISEASE: NEW DISCOVERIES FROM THE FINGERS TRIALS |
| Lynn Kramer | USA | NOVEL APPROACHES TO CLINICAL DEVELOPMENT AND THE FUTURE POTENTIAL OF SIMULATED PLACEBO |
| Frank Laferla | USA | MODELING LATE-ONSET ALZHEIMER’S DISEASE IN MICE |
| Virginia Lee | USA | MODULATORS OF TAUOPATHIES |
| Seung-Jae Lee | Korea | INHIBITION OF NEURON-TO-OLIGODENDROCYTE ALPHA-SYNUCLEIN PROPAGATION WITH AN ANTI-TLR2 ANTIBODY |
| Cynthia Lemere | USA | POTENTIAL MECHANISMS AND MITIGATION STRATEGIES FOR ANTI-AMYLOID-INDUCED ARIA |
| Frank Longo | USA | MODULATION OF THE P75 NEUROTROPHIN RECEPTOR INHIBITS MICROGLIAL DYSTROPHY AND DYSFUNCTION ASSOCIATED WITH PATHOLOGICAL FORMS OF TAU |
| Daniel M. Michaelson | Israel | ASSESSMENT OF THE ANTI APOE4 EFFICACY OF THE RECENTLY DEVELOPED ABCA1 ACTIVATOR N1 |
| Eliezer Masliah | USA | NEUROIMMUNE MODULATORY PATHWAYS IN THE THERAPEUTICS OF LEWY BODY DEMENTIA |
| Mark Mintun | USA | ADVANCES IN OUR UNDERSTANDING OF AMYLOID PLAQUE CLEARING THERAPIES |
| Asuka Morizane | Japan | CELL THERAPY FOR PARKINSON’S DISEASE WITH PLURIPOTENT STEM CELL-DERIVED DOPAMINERGIC PROGENITORS |
| John Morris | USA | EXPLORING RACIAL DIFFERENCES IN ALZHEIMER DISEASE |
| Ulrike Müller | Germany | NEUROTROPHIC AND SYNAPTOTROPHIC FUNCTIONS OF SECRETED APPS AND ITS THERAPEUTIC POTENTIAL FOR AD |
| Melissa Murray | USA | DEMOGRAPHIC AND GENETIC CONTRIBUTORS TO CORTICOLIMBIC VULNERABILITY IN YOUNG-ONSET AD |
| Manuela Neumann | Germany | ROLE OF TDP-43 PHOSPHORYLATION IN TDP-43 PROTEINOPATHIES |
| Henrietta Nielsen | Sweden | PERIPHERAL APOE SIGNATURES |
| Agneta Nordberg | Sweden | TRACKING AD SUBYPE TRAJECTORIES WITH MULTI-MODAL PET AND FLUID BIOMARKERS |
| Tiago Outerio | Germany | MODELING AND IMAGING ALPHA-SYNUCLEIN AGGREGATION: INSIGHTS INTO MOLECULAR MECHANISMS OF DISEASE |
| Ronald Petersen | USA | ALZHEIMER’S DISEASE BIOMARKERS IN THE COMMUNITY |
| Werner Poewe | Austria | PD RISK SCREENING – WHERE DO WE STAND |
| Marco Prado | Canada | CHOLINERGIC MECHANISMS IN DEMENTIA |
| Gill Rabinovici | USA | IMPLEMENTING BIOMARKERS IN REAL WORLD MEMORY CARE: LESSONS FROM THE IDEAS STUDY |
| Laura Ranum | USA | INCREASED ALZHEIMER’S RISK ASSOCIATED WITH INTRONIC CASP8 REPEAT EXPANSION |
| Philip Scheltens | The Netherlands | AD THERAPY; WHERE DO WE GO FROM HERE?? |
| Michael Schlossmacher | Canada | GENERATION OF ALPHA-SYNUCLEIN AGGREGATES IN HUMAN OLFACTORY EPITHELIA INCLUDES MUCUS-PRODUCING GLANDS |
| Menachem Segal | Israel | PRESENILIN-1 AFFECTS MITOCHONDRIA IN CULTURED HIPPOCAMPAL NEURONS: FUNCTIONAL IMPLICATIONS |
| Jie Shen | USA | LRRK2 MUTATIONS AND PARKINSON’S DISEASE |
| Tamara Shiner | Israel | GENETIC FACTORS IN CLINICAL, IMAGING AND BLOOD BIOMARKERS IN DLB |
| Sam Sisodia | USA | THE GUT MICROBIOME AND IMPACT ON AD-TYPE NEUROPATHOLOGY |
| Beka Solomon | Israel | DOWN-REGULATION OF BACE1 ACTIVITY WITHOUT AFFECTING PROCESSING OF OTHER SUBSTRATES MAY HAVE A CLINICAL VALUE FOR TREATMENT OF ALZHEIMER’S DISEASE |
| Mona Soreq | Israel | SEX‐SPECIFIC DECLINES IN CHOLINERGIC‐TARGETING TRNA FRAGMENTS IN THE NUCLEUS ACCUMBENS IN ALZHEIMER’S DISEASE |
| Maria Grazia Spillantini | UK | ALPHA-SYNUCLEIN MODELS |
| Peter St. George-Hyslop | Canada | TREM2 SIGNALLING PATHWAYS IN MICROGLIA AND PERIPHERAL BLOOD MONONUCLEAR CELLS |
| Stephen Salloway | USA | APPROPRIATE USE OF AMYLOID-LOWERING TREATMENTS |
| Beth Stevens | USA | MODELING MECHANISMS OF AD RISK AND RESILIENCE |
| Fabrizio Stocchi | Italy | HOW PARKINSON’S DISEASE TREATMENT WILL CHANGE IN THE NEXT FUTURE |
| Tom Sudhof | USA | ABETA AND SYNAPSES: A CONTENTIOUS RELATIONSHIP |
| Malu Tansey | USA | TARGETING AGE-RELATED IMMUNE DYSFUNCTION TO REDUCE RISK OF NEURODEGENERATION |
| Rudy Tanzi | USA | THE ROLE OF PERIPHERAL CELLS AND FACTORS IN ALZHEIMER’S DISEASE PATHOGENESIS |
| Charlotte Teunissen | The Netherlands | IDENTIFICIATION OF NOVEL PROTEINS AND PROTEIN PANELS IN BODY FLUIDS BY PROTEOMICS FOR VARIOUS DEMENTIA DIAGNOSES (FAMILIAL AD, AD, DLB, FTD, A+SCD). A STRATEGY TOWARDS CLINICAL USE |
| Li-Huei Tsai | USA | NEUROIMMUNE INTERACTIONS AT THE BRAIN BORDERS IN HEALTH AND DISEASE |
| Robert Vassar | USA | LOW-LEVEL BACE1 INHIBITION FOR ALZHEIMER DISEASE |
| Michael Weiner | USA | COMMUNITY ENGAGED RESEARCH USING DIGITAL MARKETING, WEB BASED ASSESSMENTS, AND BLOOD TESTS TO RECRUIT AND SCREEN UNDER REPRESENTED PEOPLE INTO THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE (ADNI) |
| Cheryl Wellington | Canada | TBA |
| Donna Wilcock | USA | UNDERSTANDING MECHANISMS OF ANTI-AMYLOID IMMUNOTHERAPY-MEDIATED ARIA EVENTS |
| Bengt Winblad | SWEDEN | DEVELOPMENT OF SMALL MOLECULES TARGETING TAU AND OTHER PROTEINS IN ALZHEIMER DISEASE |
| Henrik Zetterberg | Sweden | NOVEL BIOFLUID-BASED BIOMARKERS FOR NEURODEGENERATIVE PROCESSES ACROSS DEMENTIAS |
| Berislav Zlokovic | USA | BLOOD-BRAIN BARRIER AND VASCULAR SYSTEM AS TREATMENT TARGETS FOR COGNITIVE IMPAIRMENT AND ALZHEIMER’S’ DISEASE |